Special Oregon COVID-19 Response for Clinicians Session 10 May 21, 2020
Sign up ! “COVID-19 Response ECHO for Oregon Clinicians Part II” Registration is open for Cohort 2 of the COVID-19 ECHO • 2nd and 4th Thursday of each month, noon – 1 p.m. • Begins June 11 and continues through September 24, 2020 • You must register to receive CME for these sessions • COVID-19 ECHO Part II Objectives: 1) Provide the latest information on COVID-19 impact in Oregon; 2) Receive guidance on evidence-based management of COVID-19; 3) Forum to share clinical, community, and system cases to improve quality and inform ‘best practice’ Sign up at www.oregonechonetwork.org
1. Go to www.oregonechonetwork.org And click on the sign-up link. 2. You’ll need to log in to your Connect account and click the button to sign up for the ECHO 3
Special COVID-19 ECHO Series Goals 1. Provide the latest information on the COVID-19 pandemic and it’s impact on Oregon 2. Deliver brief didactic sessions on key areas, e.g., clinical management, hospital/critical care management, prevention, practice system & workflow, community impact, ethical issues, older adult & vulnerable populations, long term care management, etc. 3. Provide a forum to share clinical, community, and system cases to improve quality and inform ‘best practice’
Today’s Agenda • COVID-19 Update • Expert presentation: “ More Testing and Transmission of COVID- 19 AND Vaccine Update”, Mark Slifka PhD • Q & A 5
Oregon Health Authority COVID-19 Update, May 21, 2020 Dana Hargunani, MD MPH Tom Jeanne, MD, MPH 6
Agenda Items • COVID-19 epi and hospitalization data • Re-opening Oregon • Pediatric Multisystem Inflammatory Syndrome • Contact Tracing • Testing Update • On the horizon… • Closing 7
Epidemiology Update 8
The COVID-19 Pandemic Update in Oregon As of May 20: • 3,701 positive COVID-19 tests • 144 deaths • 98,348 negative tests •Test results do not reflect the full impact of COVID-19 in our state 9
Testing Results Summary through 5/15 10
Epidemiologic curve 11
Daily ED visits 12
Daily ED visits for CLI 13
Current COVID-19 Hospitalizations: May 20 Currently Currently Hospitalized Hospitalized COVID-19 COVID-19 Positive Patients* Patients** Hospitalized COVID-19 152 53 Patients COVID-19 Patients in ICU 42 25 Beds COVID-19 Patients on 17 13 Ventilators *Includes both confirmed and suspected COVID-19 patients **Includes only confirmed positive COVID-19 patients 14
Trends in COVID-19 Hospitalizations 15
Trends in COVID-19 Hospitalizations 16
Reopening Oregon 17
Phased Reopening Phase I: • Local gatherings for local groups only up to 25 (no travel) • Restaurants/bars: physical distance spacing, employees wear cloth face or disposable coverings, end all consumption by 10 pm • Personal services: by appointment, pre-appointment health check, maintain customer log, six feet physical distancing, face coverings/capes/smocks 18
19
Reopening Criteria: www.healthoregon.org/coronavirus 20
Reopening Criteria: ED visits for COVID-like illness 21
Reopening Criteria: 14-day hospital admission trends 22
Reopening Guidance: www.healthoregon.org/coronavirus 23
Reopening Guidance Statewide 24
Reopening Guidance Phase 1 25
Pediatric Multisystem Inflammatory Syndrome 26
Pediatric Multisystem Inflammatory Syndrome—CDC case definition CDC Case Definition for Multisystem Inflammatory Syndrome in Children (MIS-C) An individual aged <21 years presenting with fever i , laboratory evidence of inflammation ii , and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND No alternative plausible diagnoses; AND Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms 27
Pediatric Multisystem Inflammatory Syndrome—CDC case definition i Fever >38.0° C for ≥24 hours, or report of subjective fever lasting ≥24 hours ii Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin Additional comments • Some individuals may fulfill full or partial criteria for Kawasaki disease but should be reported if they meet the case definition for MIS-C • Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection 28
Pediatric Multisystem Inflammatory Syndrome—CDC case definition Additional CDC information: • Healthcare providers who have cared or are caring for patients younger than 21 years of age meeting MIS-C criteria should report suspected cases to their local, state, or territorial health department. • It is currently unknown if multisystem inflammatory syndrome is specific to children or if it also occurs in adults. • There is limited information currently available about risk factors, pathogenesis, clinical course, and treatment for MIS-C. First Reported PMIS Case in Oregon • OHA distributed a press release on 5/13 which can be found here: https://www.oregon.gov/oha/ERD/Pages/OHA-announces-1st-case-of-COVID-19-linked- pediatric-condition.aspx • A Health Advisory Notice was distributed to Oregon health providers on May 14th 29
Contact Tracing and Case Investigation Basics 30
Contact Tracing Oregon COVID-19 Contact Collaborative • Joint initiative of OHA, local public and tribal health authorities, and community-based organizations to reduce the spread of COVID-19 through coordinated, statewide contact tracing • Trained staff from state, local, and tribal health authorities and community-based organizations, including multilingual community members and leaders Contact tracing is a public health method used to identify people who have been exposed to an illness to help slow down the spread of the disease • Contacts of people with COVID-19 are identified during case investigation • Educate people how to prevent the spread of the virus by staying at home or at the location provided by local public health (quarantine), and how to care for themselves and others they may live with if they develop symptoms 31
Case Investigation Calls to a person with a confirmed positive COVID-19 test: • Case investigator will help them remember the places they visited and people they may have been in contact with since two days before symptoms began (contact = <6 feet from someone for >15 minutes) • Case investigator will ask for contact information for people they had contact with. A public health team member will contact those people, but they will not them any information about the person with the confirmed case. • Case investigator will provide information on isolation and preventing further spread 32
Contract Tracing Calls to a person identified as a contact of a person with COVID-19: • The Oregon COVID-19 Contact Collaborative will reach out via phone to inform them that they may have been exposed to COVID-19. They will share information about how to prevent the spread of the virus, how to care for yourself, and how to connect with resources in your community. • Even if no symptoms, they will be advised to voluntary self-quarantine for 14 days • During this time, the Contact Collaborative team will contact them daily (phone or text) to check in about any symptoms or questions they have • They will be given information on symptoms to watch for, and if they develop symptoms will be connected with resources on how to get tested 33
Contact Tracing • Contact tracing is done by telephone and mail, not in person • Information is strictly confidential • Contact tracers will ask for • County of residence • Date of birth • Contact information, including phone number, email address, and mailing address • Occupation • Symptoms of COVID-19 • Contact tracers will never ask for • Social security number • Immigration status (Information will not be shared with immigration authorities or law enforcement for immigration purposes) • Credit card number, bank account, or billing information 34
Testing Update 35
Antibody testing Serology testing, which looks for antibodies in blood, is increasingly available: 12 tests have FDA EUA • OHA recommends against using any COVID-19 test that does not have FDA EUA • List of all tests with FDA Emergency Use Authorization: https://www.fda.gov/medical- devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd Antibody testing is not recommended for diagnosis or exclusion of COVID-19 When using antibody testing, notify patients of limitations of the test • Still unknown whether antibodies confer full or partial immunity to COVID-19 or for how long. • Cross-reactivity with other coronaviruses may be a concern • EUA ≠ FDA approval 36
Recommend
More recommend
